Ademi LLP Investigates Claims of Securities Fraud against The Chemours Company
Werte in diesem Artikel
MILWAUKEE, Feb. 29, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Chemours (NYSE: CC). The investigation results from inaccurate statements Chemours may have made regarding its accounting, business operations and prospects.
Click here to learn more about the investigation: https://www.ademilaw.com/case/chemours-company or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
The investigation focuses Chemours' determination of material weaknesses in its internal controls over financial reporting. To address these concerns, the Chemours' board has placed President and Chief Executive Officer Mark Newman, Senior Vice President and Chief Financial Officer Jonathan Lock and Vice President, Controller and Principal Accounting Officer Camela Wisel on administrative leave pending internal investigations.
If you wish to obtain additional information or have information about this investigation, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, https://www.ademilaw.com/case/chemours-company.
We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Ademi LLP
Guri Ademi
3620 East Layton Ave.
Cudahy, WI 53110
Toll Free: (866) 264-3995
Fax: (414) 482-8001
www.ademilaw.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ademi-llp-investigates-claims-of-securities-fraud-against-the-chemours-company-302075983.html
SOURCE Ademi LLP
Ausgewählte Hebelprodukte auf The Chemours
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf The Chemours
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle The Chemours Aktie News
The Chemours Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für The Chemours nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 29.03.18 | The Chemours Outperform | BMO Capital Markets | |
| 07.08.17 | The Chemours Neutral | UBS AG | |
| 09.05.16 | The Chemours Overweight | Barclays Capital | |
| 18.09.15 | The Chemours Hold | Argus Research Company | |
| 18.08.15 | The Chemours Sell | UBS AG |
